Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A solid pharmaceutical composition, comprising a synergistic combination of glimepiride and metformin hydrochloride, wherein the weight ratio of glimepiride and metformin hydrochloride is about 1/500, and wherein the combination of glimepiride and metformin hydrochloride reduces blood glucose levels in a patient with type 2 diabetes greater than either glimepiride or metformin hydrochloride alone.

2. (canceled)

3. (canceled)

4. (currently amended) [[A]] The solid pharmaceutical composition according to claim 1, comprising 500 mg metformin hydrochloride, 1 mg glimepiride, and at least one excipient.

5. (canceled)

6. (currently amended) [[A]] The solid pharmaceutical composition according to claim 1, comprising 1000 mg metformin hydrochloride, 2 mg glimepiride, and at least one excipient.

7. (canceled)

8. (currently amended) A method of controlling blood glucose levels in a patient with type 2 diabetes, comprising administering to said patient a synergistic combination of glimepiride and metformin hydrochloride, in a solid dosage form, wherein the weight ratio of glimepiride and metformin hydrochloride is about 1/500, and wherein the combination of glimepiride and metformin hydrochloride reduces blood glucose levels in a patient with type 2 diabetes greater than either glimepiride or metformin hydrochloride alone.

9. (canceled)

10. (canceled)

11. (currently amended) [[A]] The method according to claim 8, comprising administering a composition wherein glimepiride and metformin hydrochloride are present in amounts of 1 mg glimepiride and 500 mg metformin hydrochloride ~~and~~ or 2 mg glimepiride and 1000 mg metformin hydrochloride.

12. (new) The method according to claim 8, comprising administering a composition wherein glimepiride and metformin hydrochloride are present in amounts of 1 mg glimepiride and 500 mg metformin hydrochloride.

13. (new) The method according to claim 8, comprising administering a composition wherein glimepiride and metformin hydrochloride are present in amounts of 2 mg glimepiride and 1000 mg metformin hydrochloride.

14. (new) The solid pharmaceutical composition according to claim 1, wherein the combination of glimepiride and metformin hydrochloride

reduces blood glucose levels in a patient with type 2 diabetes greater than the additive effect of glimepiride and metformin hydrochloride alone.

15. (new) The method according to claim 8, wherein the combination of glimepiride and metformin hydrochloride reduces blood glucose levels in a patient with type 2 diabetes greater than the additive effect of glimepiride and metformin hydrochloride alone.

16. (new) The solid pharmaceutical composition according to claim 1, wherein the combination of glimepiride and metformin hydrochloride reduces glycosylated hemoglobin levels in a patient with type 2 diabetes greater than either glimepiride or metformin hydrochloride alone.

17. (new) The method according to claim 8, wherein the combination of glimepiride and metformin hydrochloride reduces glycosylated hemoglobin levels in a patient with type 2 diabetes greater than either glimepiride or metformin hydrochloride alone.

18. (new) The solid pharmaceutical composition according to claim 16, wherein the combination of glimepiride and metformin hydrochloride reduces glycosylated hemoglobin levels in a patient with type 2 diabetes greater than the additive effect of glimepiride and metformin hydrochloride alone.

19. (new) The method according to claim 17, wherein the combination of glimepiride and metformin hydrochloride reduces glycosylated hemoglobin levels in a patient with type 2 diabetes greater than the additive effect of glimepiride and metformin hydrochloride alone.

20. (new) The solid pharmaceutical composition according to claim 1, further comprising microcrystalline cellulose, croscarmellose sodium, and povidone.

21. (new) The solid pharmaceutical composition according to claim 20, further comprising colloidal silicon dioxide, magnesium stearate, and opadry clear.

22. (new) The solid pharmaceutical composition according to claim 1, further comprising about 18 mg to about 36 mg of povidone, about 3 mg to about 6 mg of magnesium stearate, and about 1.8 mg to about 3.6 mg of colloidal silicon dioxide.

23. (new) The solid pharmaceutical composition according to claim 22, further comprising about 18 mg of povidone, about 3 mg of magnesium stearate, and about 1.8 mg of colloidal silicon dioxide.

24. (new) The solid pharmaceutical composition according to claim 22, further comprising about 36 mg of povidone, about 6 mg of magnesium stearate, and about 3.6 mg of colloidal silicon dioxide.

25. (new) The solid pharmaceutical composition according to claim 4, further comprising about 18 mg of povidone, about 3 mg of magnesium stearate, and about 1.8 mg of colloidal silicon dioxide.

26. (new) The solid pharmaceutical composition according to claim 6, further comprising about 36 mg of povidone, about 6 mg of magnesium stearate, and about 3.6 mg of colloidal silicon dioxide.